ID   Sp2/mIL-6
AC   CVCL_C561
SY   Sp2/MIL6; SP2-IL6
DR   CLO; CLO_0009116
DR   ATCC; CRL-2016
DR   Wikidata; Q54955453
RX   PubMed=1373425;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transfected with: MGI; MGI:96559; Il6.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C125417; Mouse plasma cell myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 30-01-24; Version: 12
//
RX   PubMed=1373425; DOI=10.1016/0022-1759(92)90173-q;
RA   Harris J.F., Hawley R.G., Hawley T.S., Crawford-Sharpe G.C.;
RT   "Increased frequency of both total and specific monoclonal antibody
RT   producing hybridomas using a fusion partner that constitutively
RT   expresses recombinant IL-6.";
RL   J. Immunol. Methods 148:199-207(1992).
//